drugset / Trial / NCT00536731
Symbicort Rapihaler Therapeutic Equivalence Study
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of the this study is to evaluate the efficacy and safety of 2 actuations Symbicort®pMDI® 40/2.25 μg twice daily compared with1 inhalation Symbicort Turbuhaler® 80/4.5 μg twice daily and 1 inhalation Pulmicort®Turbuhaler® 100 μg twice daily for 6 weeks.
Timeline
- Start
- 2007-09
- Primary completion
- 2008-04
- Completion
- 2008-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Budesonide | Small molecule | 100 ug | Inhaled |
| Comparator | Symbicort | Unknown | — | Inhaled |